Related Experiment Video
Updated: Jul 19, 2026
Antigen-Capture Enzyme-Linked Immunosorbent Assay for Specific Detection of Mycoplasma pneumoniae
Published on: February 24, 2023
Identification of Mycoplasma pneumoniae-associated pneumonia cases among hospitalized patients using CLART®
Enty Tjoa1, Shikha Joon2, Lucky Hartati Moehario1
1Department of Microbiology, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jakarta, Indonesia.
Objectives:
Community-acquired pneumonia (CAP) is a global health condition that affects populations from all age groups. The laboratory identification of Mycoplasma pneumoniae as a causative agent of CAP is challenging because of its atypical and fastidious nature. Therefore, this study assessed the diagnostic potential of PneumoCLART bacteria® in identifying M. pneumoniae as a causative agent of pneumonia in hospitalized adults.
Methods:
This prospective study used a cross-sectional approach to assess the diagnostic potential of PneumoCLART bacteria® for detecting M. pneumoniae in sputum samples procured from 27 patients with pneumonia who required hospitalization.
Results:
The PneumoCLART bacteria® results illustrated that 7 of 27 patients with pneumonia were positive for M. pneumoniae (26%). However, the quality of sputum varied among the M. pneumoniae-positive and M. pneumoniae-negative samples. Fifty percent of the specimens obtained from patients positive for M. pneumoniae were saliva-contaminated and unsuitable for analysis.
Conclusions:
Because the leukocyte count was low and sputum specimens were saliva-contaminated, these findings require further validation to prove the utility of CLART® microarray technology for the identification of M. pneumoniae in pneumonia-positive patients. Conclusively, this prospective study included a small number of clinical samples, which likely affected its outcomes.
Insights
Diagnosing Mycoplasma pneumoniae in community-acquired pneumonia (CAP) is difficult. A study using PneumoCLART bacteria® showed potential but requires further validation due to sample contamination and small patient numbers.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Diagnostic Technology
Background:
- Community-acquired pneumonia (CAP) is a significant global health concern.
- Identifying Mycoplasma pneumoniae as a CAP cause is challenging due to its unique characteristics.
- Accurate laboratory identification of M. pneumoniae is crucial for effective treatment.
Purpose of the Study:
- To evaluate the diagnostic capability of PneumoCLART bacteria® for M. pneumoniae detection.
- To assess the utility of this technology in hospitalized adult pneumonia patients.
- To determine the prevalence of M. pneumoniae in the studied cohort.
Main Methods:
- A prospective, cross-sectional study design was employed.
- Sputum samples were collected from 27 hospitalized pneumonia patients.
- PneumoCLART bacteria® was used for M. pneumoniae identification.
Main Results:
- Mycoplasma pneumoniae was detected in 7 out of 27 patients (26%).
- A significant portion (50%) of M. pneumoniae-positive samples were saliva-contaminated and unsuitable for analysis.
- Low leukocyte counts were also noted in some samples.
Conclusions:
- The CLART® microarray technology shows potential for M. pneumoniae identification.
- Further validation is necessary due to issues with sputum quality and sample contamination.
- The small sample size limits the definitive conclusions of this study.
Related Concept Videos
01:30Pneumonia III: Complications and Assessment
01:25Rapid Identification of Pathogens
01:24Automated Microbial Diagnostics
01:14Atypical Pneumonia